FBIO - Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference | Benzinga
MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer, will present a corporate update at the Sidoti January Micro-Cap Investor Conference on Thursday, January 18, 2024 at 10:00 a.m. EST.
A webcast and subsequent archived replay of the company presentation will be available on the Events page of Avenue's website: https://avenuetx.com/ for approximately 90 days following the meeting.
Avenue Therapeutics will also host virtual one-on-one meetings with investors on Wednesday, January 17 and Thursday, January 18. To register for the conference and schedule a one-on-one meeting, please visit https://sidoti.com/events.
About Avenue Therapeutics
Avenue Therapeutics, Inc. (NASDAQ:ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. It is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABAA ?2/3 receptor positive allosteric modulator for CNS diseases, and IV tramadol, which is in Phase 3 clinical development for the management of acute postoperative pain ...